This year’s IOA Sylvan M. Cohen Annual Retreat focused on fluid biomarkers, the next wave of diagnostic tools in Alzheimer’s disease (AD).
“Biomarkers are an important part of dementia research. They help researchers detect early brain changes, better understand how risk factors are involved, identify participants who meet particular requirements for clinical trials and studies, and track participants’ responses to a test drug or other intervention, such as physical exercise.” – nia.nih.gov
Topics covered included an update on biofluid-based biomakers for amyloid and neurodegeneration by Henrik Zetterberg, MD, PhD, professor at the University of Gothenburg, Sweden, and University College London, and plasma tau biomarkers in acute and chronic neurological diseases by Thomas Karikari, PhD, assistant professor at the University of Pittsburgh.
Several Penn presenters also shared their research in the field. This year’s lineup included Katheryn A.Q. Cousins, PhD, Tom Tropea, DO, MPH, MTR, Les Shaw, PhD, Jina Ko, PhD, and Ramon Diaz-Arrastia, MD, PhD.
“My hope is that we develop biomarkers for non-AD pathologies.” said Eddie Lee, MD, PhD, neuropathologist and co-director of the IOA, when asked about his thoughts on the future of biomarkers in AD research. “We desperately need things for TDP-43, alpha-synuclein, other proteinopathies.”
2022 Poster Winners